Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on B-cell diseases, with news flow centered on its CD20-targeted monoclonal antibody BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). This news page aggregates company announcements, clinical data updates, financial results, and corporate presentations related to TGTX stock.
Recent press releases highlight preliminary and reported revenue from BRIUMVI, including disclosures that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners. Investors can follow updates on revenue guidance, operating expense targets, and commentary on how BRIUMVI commercialization influences overall company performance.
TG Therapeutics also issues frequent news about its development programs. These items include progress in the ENHANCE Phase 3b trial evaluating a simplified intravenous dosing schedule for BRIUMVI, the Phase 3 pivotal program for subcutaneous ublituximab, and the Phase 1 trial of azer-cel, an allogeneic CD19 CAR T therapy in autoimmune disease. Additional releases cover long-term ULTIMATE I & II trial data, real-world ENABLE observational study outcomes, and schedules of data presentations at neurology and multiple sclerosis congresses.
Corporate news includes participation in major healthcare and biotechnology investor conferences, rankings such as the Deloitte Technology Fast 500, and announcements of share repurchase authorizations. By following this TGTX news feed, readers can monitor how clinical results, regulatory milestones, commercialization updates, and financial disclosures intersect for TG Therapeutics and its lead therapy BRIUMVI.
TG Therapeutics (NASDAQ: TGTX) secured a new five-year $750 million senior secured credit facility with funds managed by Blue Owl, repaid its prior $250 million facility and thus raised 500 million of net non-dilutive capital. The facility can be increased by $250 million to a total of $1 billion at mutual discretion.
The Board expanded the share repurchase program from $100 million to $300 million; as of March 18, 2026 the company repurchased about $38 million of stock at an average price of $28.98. Further credit-facility details will be filed on Form 8-K.
Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.
The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.
TG Therapeutics (NASDAQ: TGTX) published a post hoc pooled analysis from Phase 3 ULTIMATE I and II showing BRIUMVI (ublituximab) produced large, statistically significant reductions in relapses and MRI activity versus teriflunomide in people with highly active relapsing MS.
Key results: ARR 0.145 vs 0.496 (70.8% reduction), early and sustained lesion reductions through Week 96, and markedly higher NEDA-3 rates (77.9% vs 16.4% during Weeks 24–96).
TG Therapeutics (NASDAQ: TGTX) announced the schedule of data presentations for BRIUMVI (ublituximab-xiiy) at the American Academy of Neurology (AAN) 2026 annual meeting, April 18–22 in Chicago. Two poster presentations on April 21 cover real-world ENABLE Phase 4 experience and ENHANCE safety/tolerability updates. Abstracts are available on the AAN website and data will be posted to the company publications page.
Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.
The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.
TG Therapeutics (NASDAQ: TGTX) reported fourth-quarter 2025 total revenue of $192.6M and full-year 2025 revenue of $616.3M, driven by BRIUMVI U.S. net revenue of $182.7M (Q4) and $594.1M (FY). The company raised 2026 total global revenue guidance to $875–$900M and expects BRIUMVI U.S. revenue of $825–$850M.
Other highlights: completed a $100M repurchase and authorized an additional $100M, presented multi‑year BRIUMVI data, advanced pivotal trials including a subcutaneous program, and ended 2025 with $199.5M cash and investments.
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day replay will be available on the company's Investors & Media Events page. Financial results will be issued in a press release prior to the call.
TG Therapeutics (NASDAQ: TGTX) published five-year ULTIMATE I/II open-label extension data in JAMA Neurology showing durable efficacy and consistent safety for BRIUMVI (ublituximab) in relapsing MS.
Key highlights: 3,600+ participant-years exposure, Year‑5 ARR 0.020, >70% on treatment at Year 5, 8% 24‑week CDP with continuous treatment, and no new safety signals.
TG Therapeutics (NASDAQ: TGTX) announced a collaboration with actress Christina Applegate to raise national awareness of multiple sclerosis (MS) and foster honest conversations. The initiative launched during Super Bowl LX and introduced www.NextInMS.com, a platform with Christina’s personal perspectives and expert educational content to support people living with MS.
The campaign aims to elevate patient voices, provide resources on long-term decision-making and healthcare navigation, and encourage open dialogue among patients, caregivers, and clinicians.
TG Therapeutics (NASDAQ: TGTX) announced that multiple presentations on BRIUMVI (ublituximab) will be presented at the ACTRIMS annual forum in San Diego on Feb 6, 2026. Presentations include ENABLE real‑world infusion data and pediatric ULTIMATE KIDS I and II study designs.
Posters and ePosters are available on the company publications page and the ACTRIMS ePoster gallery.